Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
At a glance
Conditions
Where it's being run
2 sites across 2 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Allergic reaction (IgA) vasculitis7 days
1. The disappearance of palpable purpura is a direct manifestation of recovery. Observe whether there are new subcutaneous bleeding points on the patient's body, and whether the original purpura color gradually changes from purple red to yellow brown until it disappears. Some patients may have temporary pigmentation, but it will not continue to expand or recur. 2. Joint pain disappears. Patients with hypersensitivity reaction (IgA) vasculitis answered in the questionnaire that the swollen joint pain was relieved and their mobility was restored, indicating that the inflammation was under control. Diagnosis can also be made through C-reactive protein testing. 3. No proteinuria (24-hour urine protein below 0.4g/24 hours). Urine routine examination can detect protein indicators in urine to evaluate kidney function. 4. The serum albumin level is 35g-55g/L. Serum creatinine is below 1.24mg/dL. Perform blood biochemical tests on serum albumin and serum creatinine to evaluate renal function.